Belite Bio (STU:D01) Interest Expense: €-0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:D01 Belite Bio Inc STU:D01
20 GF Score
Price €131.00
! 3 Warning Signs
View Full Analysis

What is Belite Bio Interest Expense?

Belite Bio STU:D01 +1.55% 20 Interest Expense is €-0.00 Mil as of Mar. 2026. GuruFocus rates STU:D01 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Belite Bio's interest expense for the three months ended in Mar. 2026 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Belite Bio's Operating Income for the three months ended in Mar. 2026 was € -28.27 Mil. Belite Bio's Interest Expense for the three months ended in Mar. 2026 was € 0.00 Mil. Belite Bio has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Belite Bio  (STU:D01) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Belite Bio's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-28.27 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.00 Mil.

Belite Bio's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Belite Bio had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Belite Bio Interest Expense Historical Data

* Premium members only.

The historical data trend for Belite Bio's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Belite Bio Interest Expense Chart

Belite Bio Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial 0.00 -0.02 -0.02 -0.02 -0.00

Belite Bio Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
STU:D01
20GF Score
Belite Bio Inc STU:D01
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Belite Bio Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €-0.00 Mil mean?
Belite Bio (STU:D01) has a Interest Expense of €-0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Belite Bio and its competitors.
Is Belite Bio's Interest Expense too high?
Belite Bio's current Interest Expense is €-0.00 Mil. Overall, Belite Bio has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Belite Bio's Interest Expense compare to DFTX and LGND?
Belite Bio's Interest Expense of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Belite Bio and its competitors. Belite Bio's current Interest Expense is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Belite Bio stock overvalued right now?
Belite Bio (STU:D01) has a current Interest Expense of €-0.00 Mil. The current Interest Expense is €-0.00 Mil. Belite Bio's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Belite Bio (STU:D01), the current Interest Expense is €-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Belite Bio Business Description

Other Exchanges BLTE:USA
Address 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
20GF Score

Get the complete analysis for STU:D01

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€131.00
Price